Cargando…

Adherence to anti-seizure medications in the Swedish Prospective Regional Epilepsy Database and Biobank for Individualized Clinical Treatment (PREDICT)

The aim of this study was to describe the extent of, and risk factors for, non-adherence to anti-seizure medications (ASMs) in adult people with epilepsy (PWE) in Sweden. A cross-sectional multi-centre study was performed of PWEs in western Sweden, with data from medical records, and a questionnaire...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrén, Kerstin, Larsson, David, Asztély, Fredrik, Zelano, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641594/
https://www.ncbi.nlm.nih.gov/pubmed/37965624
http://dx.doi.org/10.1016/j.ebr.2023.100631
_version_ 1785146802531467264
author Andrén, Kerstin
Larsson, David
Asztély, Fredrik
Zelano, Johan
author_facet Andrén, Kerstin
Larsson, David
Asztély, Fredrik
Zelano, Johan
author_sort Andrén, Kerstin
collection PubMed
description The aim of this study was to describe the extent of, and risk factors for, non-adherence to anti-seizure medications (ASMs) in adult people with epilepsy (PWE) in Sweden. A cross-sectional multi-centre study was performed of PWEs in western Sweden, with data from medical records, and a questionnaire filled in by the participants including self-reports on how often ASM doses had been forgotten during the past year. Participants were categorized into adherent if they forgot at 0–1 occasion, and non-adherent if they forgot at 2–10 or >10 occasions. Demographic and clinical factors were compared by Chi2- or Fisher’s test and a logistic regression model was used to find risk factors for non-adherence. In the cohort of 416 PWE aged median 43, IQR 29–62 years, 398 patients were prescribed ASM treatment at inclusion, and 39 % (n = 154) were in the non-adherent group. Significant factors in the multivariable analysis were: younger age, seizure freedom the past year, valproate treatment and experiencing side effects. The rate of self-reported non-adherence was high, illustrating a need for continuous focus on fundamental aspects of epilepsy care. The identified risk factors could enable quality improvement projects and patient education to be directed to those at risk of non-adherence.
format Online
Article
Text
id pubmed-10641594
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-106415942023-11-14 Adherence to anti-seizure medications in the Swedish Prospective Regional Epilepsy Database and Biobank for Individualized Clinical Treatment (PREDICT) Andrén, Kerstin Larsson, David Asztély, Fredrik Zelano, Johan Epilepsy Behav Rep Article The aim of this study was to describe the extent of, and risk factors for, non-adherence to anti-seizure medications (ASMs) in adult people with epilepsy (PWE) in Sweden. A cross-sectional multi-centre study was performed of PWEs in western Sweden, with data from medical records, and a questionnaire filled in by the participants including self-reports on how often ASM doses had been forgotten during the past year. Participants were categorized into adherent if they forgot at 0–1 occasion, and non-adherent if they forgot at 2–10 or >10 occasions. Demographic and clinical factors were compared by Chi2- or Fisher’s test and a logistic regression model was used to find risk factors for non-adherence. In the cohort of 416 PWE aged median 43, IQR 29–62 years, 398 patients were prescribed ASM treatment at inclusion, and 39 % (n = 154) were in the non-adherent group. Significant factors in the multivariable analysis were: younger age, seizure freedom the past year, valproate treatment and experiencing side effects. The rate of self-reported non-adherence was high, illustrating a need for continuous focus on fundamental aspects of epilepsy care. The identified risk factors could enable quality improvement projects and patient education to be directed to those at risk of non-adherence. Elsevier 2023-10-29 /pmc/articles/PMC10641594/ /pubmed/37965624 http://dx.doi.org/10.1016/j.ebr.2023.100631 Text en © 2023 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Andrén, Kerstin
Larsson, David
Asztély, Fredrik
Zelano, Johan
Adherence to anti-seizure medications in the Swedish Prospective Regional Epilepsy Database and Biobank for Individualized Clinical Treatment (PREDICT)
title Adherence to anti-seizure medications in the Swedish Prospective Regional Epilepsy Database and Biobank for Individualized Clinical Treatment (PREDICT)
title_full Adherence to anti-seizure medications in the Swedish Prospective Regional Epilepsy Database and Biobank for Individualized Clinical Treatment (PREDICT)
title_fullStr Adherence to anti-seizure medications in the Swedish Prospective Regional Epilepsy Database and Biobank for Individualized Clinical Treatment (PREDICT)
title_full_unstemmed Adherence to anti-seizure medications in the Swedish Prospective Regional Epilepsy Database and Biobank for Individualized Clinical Treatment (PREDICT)
title_short Adherence to anti-seizure medications in the Swedish Prospective Regional Epilepsy Database and Biobank for Individualized Clinical Treatment (PREDICT)
title_sort adherence to anti-seizure medications in the swedish prospective regional epilepsy database and biobank for individualized clinical treatment (predict)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641594/
https://www.ncbi.nlm.nih.gov/pubmed/37965624
http://dx.doi.org/10.1016/j.ebr.2023.100631
work_keys_str_mv AT andrenkerstin adherencetoantiseizuremedicationsintheswedishprospectiveregionalepilepsydatabaseandbiobankforindividualizedclinicaltreatmentpredict
AT larssondavid adherencetoantiseizuremedicationsintheswedishprospectiveregionalepilepsydatabaseandbiobankforindividualizedclinicaltreatmentpredict
AT asztelyfredrik adherencetoantiseizuremedicationsintheswedishprospectiveregionalepilepsydatabaseandbiobankforindividualizedclinicaltreatmentpredict
AT zelanojohan adherencetoantiseizuremedicationsintheswedishprospectiveregionalepilepsydatabaseandbiobankforindividualizedclinicaltreatmentpredict